Growth Hormone Receptor Antagonism Extends Lifespan
Aging Cell · 2026
DOI: 10.1111/acel.70697 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, 2026. Verfasst von Edward O List und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Medicine and Aging, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA. Hauptthemen laut MEDLINE: Longevity, Receptors, Somatotropin, Human Growth Hormone. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Interventions that disrupt growth hormone (GH) action are recognized as some of the most potent methods for extending lifespan. Accordingly, GH receptor antagonists (GHA) represent potential therapeutics to improve healthspan. Somavert (Pegvisomant for injection), used for treating patients with acromegaly, is currently the only FDA approved GHA. This drug was based on our laboratory's early 1990s discovery that mutating a codon for a conserved glycine—at position 119 in bovine GH or 120 in human GH—to a variety of amino acids, including lysine, ultimately converted GH from an agonist to antagonist. Since Pegvisomant has poor affinity to rodent GHR, it has not been tested for its ability to extend lifespan in rodents. To address this gap, we evaluated survival in GHA transgenic mice, a mouse line that played a crucial role in the discovery and development of Pegvisomant and has been maintained in our lab since 1991. While a prior study with several limitations failed to detect lifespan extension in GHA mice, our current study addressing these limitations shows that both median and maximal lifespan were significantly increased in male ( p = 0.044; p = 0.0037) and female GHA mice ( p = 2 × 10 −8 ; p = 9 × 10 −6 ), with maximal lifespan extended by 186 and 265 days, respectively. Analysis of an independent cohort of 2‐year‐old mice revealed that GHA males and females were less frail with enhanced grip strength despite increased adiposity. These findings demonstrate for the first time that GH antagonism can improve health and extend lifespan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Molecular Medicine and Aging, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA.
- The Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA.
ORCID-Profile: Edward O List
Förderung
- NIA NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
List, E. O., Berryman, D. E., Lach, G. S., Minto, D. F., Weese, K., & Kopchick, J. J. (2026). Growth Hormone Receptor Antagonism Extends Lifespan. Aging Cell. https://doi.org/10.1111/acel.70697
Vancouver
List EO, Berryman DE, Lach GS, Minto DF, Weese K, Kopchick JJ. Growth Hormone Receptor Antagonism Extends Lifespan. Aging Cell. 2026. doi:10.1111/acel.70697
BibTeX
@article{List2026,
author = {List, Edward O and Berryman, Darlene E and Lach, Grace S and Minto, Delaney F and Weese, Keeley and Kopchick, John J},
title = {Growth Hormone Receptor Antagonism Extends Lifespan},
journal = {Aging Cell},
year = {2026},
doi = {10.1111/acel.70697}
}
EUVIMED